A. Surveillance B. Proceed with cystectomy C. Switch to avelumab maintenance D. Switch to erdafitinib maintenance E. Unsure

A. Objective response rate (ORR) was greater than 60% regardless of PD-L1 expression B. Median progression-free survival (PFS) was less than 6 months regardless of PD-L1 expression C. Low expression of PD-L1 was associated with ORR less than 10% D. More than 50% of patients experienced severe adverse effects (grade 3 or higher) E. Unsure

A. Both regimens demonstrated an OS benefit over sunitinib monotherapy regardless of PD-L1 expression B. Patients with favorable-risk disease had improved survival on sunitinib monotherapy C. Any grade treatment-related adverse events were significantly higher with combination therapy D. Avelumab/axitinib failed to demonstrate an OS benefit in the intent-to-treat population E. Unsure

A. Ocular disorders, nausea, and hand-foot syndrome B. Diarrhea, hypothyroidism, and transaminase elevation C. Thromboembolic events, hypertension, and nausea D. Fatigue, QT prolongation, and proteinuria E. Unsure

A. Discontinue ipilimumab/nivolumab and initiate prednisone 1-2 mg/kg/day B. Continue ipilimumab/nivolumab and initiate topical triamcinolone cream BID–TID C. Continue ipilimumab/nivolumab and initiate infliximab 5 mg/kg once every 2 weeks D. Switch from ipilimumab/nivolumab to sunitinib E. Unsure